ABOUT THIS STUDY
Receipt of at least 1 dose of investigational product (etanercept) and participation for approximately 96 weeks in study 0881A1-3338 (B1801014)
Personally signed and dated informed consent document (and assent document, as applicable) indicating the subject (or legally representative/guardian) has been informed of all pertinent aspects of the study.
Exclusion criteria for subject planning to continue investigational product:
withdrawal from investigational product in study 0881A1-3338 for any reason (safety or
History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Westmead, Sydney, New South Wales
- Parkville, Melbourne, Victoria
- Bucaramanga, Santander
- Praha 2,
- Praha 2,
- Saint Augustin,
- Chieti Scalo,
- Mexico, D.f.
- Esplugues de Llobregat, Barcelona